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ORIGINAL ARTICLE
A modeling study of functional magnetic resonance imaging to individualize
target definition of seminal vesicles for external beam radiotherapy
Sidsel Damkjæra, Jakob B. Thomsena, Svetlana I. Petersena, Jens Peter Bangsgaarda, Peter M. Petersena,
Ivan R. Vogeliusa and Marianne C. Aznarb
aDepartment of Oncology, Section of Radiotherapy, Rigshospitalet, Copenhagen, Denmark; bClinical Trial Service Unit – Nuffield Department
of Population Health, University of Oxford, Oxford, UK
ABSTRACT
Background: Pre-treatment magnetic resonance imaging (MRI) can give patient-specific evaluation of
suspected pathologically involved volumes in the seminal vesicles (SV) in prostate cancer patients. By
targeting this suspicious volume we hypothesize that radiotherapy is more efficient without introduc-
ing more toxicity. In this study we evaluate the concept of using MRI-defined target volumes in terms
of tumor control probability (TCP) and rectal normal tissue complication probability (NTCP).
Material and methods: Twenty-one high-risk prostate cancer patients were included. Pre-treatment
CT images, T2 weighted (T2w) MRI and two multi-parametric MRI were acquired. Overlap between a
suspicious volume in the SV observed on T2w images and a suspicious volume observed on either
multi-parametric MRI was assumed to reflect a true malignant region (named ‘MRI positive’). In add-
ition the entire SV on the CT-scan was delineated. Three treatment plans of 2Gy 39 fractions were
generated per patient: one covering the MRI positive volume in SV and prostate with margin of 11mm
to the MRI positive in the SV and two plans covering prostate and SV using 11 and 7mm SV margin,
respectively. All plans were prescribed the same PTV mean dose. Rectal NTCP grade 2 was evaluated
with the Lyman–Kutcher–Burman model and TCP was estimated by a logistic model using the
combined MRI positive volume in SV and prostate as region-of-interest.
Results: Fourteen of twenty-one patients were classified as MRI positive, six of which had suspicious
volumes in all three MRI modalities. On average TCP for the plan covering prostate and the MRI posi-
tive volume was 3% higher (up to 11%) than the two other plans which was statistically significant.
The increased TCP was obtained without increasing rectal NTCP grade 2.
Conclusions: Using functional MRI for individualized target delineation in the SV may improve the
treatment outcome in radiotherapy of prostate cancer without increasing the rectal toxicity.
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Introduction
High-risk prostate cancer patients have an increased probabil-
ity of seminal vesicles (SV) involvement especially in the prox-
imal 2 cm [1]. The mobility of the prostate and the SV during
a course of radiotherapy, both in between fractions and dur-
ing a single fraction, is well-documented [2]. Inter-fraction vari-
ation of the prostate position is usually dealt with by applying
adequate margins and using fiducial markers in combination
with daily imaging. However, when the SV is part of the target
volume, the relative motion of the two organs needs to be
taken into account. The standard deviation of the daily vari-
ation of the center of mass for the SV is reported to be
2.6mm in [3] which agrees with other reported results [2]. It
has been shown that a margin of 11mm around the SV
ensures dose coverage when daily image guidance without
rotational correction is used on the prostate [3,4]. However,
adding such large margins may increase the dose to the rec-
tum and bladder and, as a result, the risk of toxicity.
Pre-treatment functional magnetic resonance imaging
(MRI) can give a patient-specific evaluation of suspected
pathologically involved volumes in prostate cancer patients
[5–8]. For this study we used the two functional scans diffu-
sion weighted imaging (DWI) and dynamic contrast
enhanced (DCE) MRI. We assumed that the two functional
scans together with the anatomical T2 weighted (T2w) MRI
could define the target volume in SV and consequently
tumor control. Under this assumption we investigated the
impact on tumor control probability (TCP) and normal tissue
complication probability (NTCP) for different planning target
volume (PTV) strategies. The aim was to compare three dif-
ferent PTV strategies and evaluate the treatment plans by
the TCP and NTCP for rectal toxicity.
Material and methods
Twenty-four consecutive prostate cancer patients referred to
radiotherapy with an intact prostate scanned between March
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2015 and April 2016 were enrolled in the study; three of
these patients were excluded due to poor quality of the
functional MRI scans. All patients were classified as high-risk
patients: PSA 10 and/or Gleason score 7 and/or T
stage T2b (see supplementary material S1). This work was
performed as a retrospective quality assurance study of cur-
rent clinical practice.
Imaging protocol
The radiotherapy planning CT was performed on a Siemens
Somatom Definition AS 64-slice scanner (Siemens
Healthineers, Erlangen, Germany) with Combifix fixation
(CIVCO Medical solutions, Orange City, LA) and a slice thick-
ness of 2mm. Pre-treatment MRI was acquired on a Siemens
Magnetom Espree 1.5 T scanner (Siemens Healthineers,
Erlangen, Germany) using the same fixation. A surface coil
placed directly on the patient was used. An imaging protocol
of 28min containing sequences described below was per-
formed. A transverse T2 weighted turbo spin echo sequence
was acquired with TR¼ 4100ms, TE¼ 93ms, a field-of-view
of 250mm and voxel size of 0.8 0.8 3mm. The DWI
sequence was performed with b¼ 0, 500 and 1000,
TR¼ 3200ms, TE¼ 104ms, fat saturation and voxel size of
2 24mm. The apparent diffusion coefficient (ADC) map
was calculated online using the Siemens scanner software
(Syngo MR Acquisition Workplace, Numaris/4, version Syngo
MR B19) including all b values. Prior to DCE imaging, two T1
weighted sequences with flip angles of 2 and 15 degrees,
respectively, were obtained for absolute T1 values needed
for modeling. Following injection of Gadovist contrast agent
(Bayer Pharma AG, Berlin, Germany, injected in a concentra-
tion of 1.0mmol per ml, 0.1ml per kg, maximum 10ml) a T1
weighted sequence was repeated 50 times to monitor con-
trast enhancement over a time period of 6min. For this
sequence, TR¼ 5.03ms, TE¼ 1.71ms and the voxel size
1.5 1.5 3mm. Calculation of the transfer constant Ktrans
was performed using the module ‘Syngo Tissue 4D’ in Syngo
Multimodality Workplace (Syngo B19 VE52A, Siemens
Healthineers, Erlangen, Germany) fitting the data to the Toft
model with extraction of Ktrans [9]. A generic arterial input
function appropriate of the prostate was used instead of an
individual measurement in order to avoid measurement
uncertainties. For Ktrans we used a routine within the software
to correct for motion between successive images. The correc-
tion was visually inspected.
CT and MRI were performed on the same day and approxi-
mately 1 hour apart. Registration between the scans was done
on inserted Nickel–Titanium based implanted markers
(BeammarksVR , Beampoint AB, Kista, Sweden) with a dimension
of 2 5mm. The markers were also used for daily setup prior
to each fraction of radiotherapy. Patients were given laxatives
and scanned/treated with comfortable filled bladder.
Structure delineation
SV, rectum, bladder and femoral heads were delineated in
the planning CT by an experienced radiation oncologist
following department guidelines. Current clinical practice in
our clinic for high-risk patients is to include the 2 cm prox-
imal part of the SV in the treatment volume as recom-
mended [1], except for patients with clinical stage T3b where
the entire SV is included. The delineation of the SV were
extended for all patients for this study to include the entire
organ and defined as the CTV for the SV (CTV_SV). The outer
contour of the rectum was extended in the target region of
the largest PTV in all cases. Study delineations of the rectum
and SV were performed by a medical physicist, where the SV
delineations were reviewed by either a radiologist or a radi-
ation oncologist. Delineations of suspicious volumes in the
T2w image and in the functional MRIs were performed by an
experienced (>10 year) radiation oncologist, in a separate
session, but not blinded. The contour of the prostate
(CTV_prostate) was adopted without modifications from the
clinical delineation based on the T2w images, and transferred
by rigid registration based on the implanted markers to the
planning CT. A rigid manual registration of the Ktrans and
ADC maps to the T2w image was performed to account for
motion between sequences.
Positive volumes in the different MR images were con-
toured retrospectively for the purpose of this study: in the
T2w images, hypointense volumes were defined as GTVs if
they could be distinguished from the surrounding anatomy
[5]. Volumes within the prostate were included in the GTV if
it was hypointense and asymmetrical (particularly in the
transverse slice) or poorly defined and/or disrupted transition
between the zones of the prostate. The GTV volume in the
SV was required to be contiguous and visible in at least two
abutting slices. In the Ktrans map, extracted from the DCE
sequence, volumes were included in the GTV if it was hyper-
intense and was within the SV or prostate. Transitions
between different tissues were difficult to identify in the
Ktrans maps and, therefore, the T2w images were used for
anatomical guidance when needed. In the ADC map calcu-
lated from the DWI, hypointense volumes were delineated as
GTV if they were within either the SV or the prostate. The
anatomy was easier to determine compared to the Ktrans
map, however, the T2w images were used for anatomical
guidance when needed.
MRI defined volumes lying directly in the vicinity of setup
markers in the prostate were assumed to be artifacts and
were therefore excluded from the delineation of GTVs in the
different MR images.
Based on T2w images the GTVs were separated into SV
and prostate parts. The T2w GTV in the SV was considered
confirmed, corresponding to a ‘true malignant volume’, if
there was an overlap with either the GTV found in the ADC
map and/or GTV in the Ktrans map. This confirmed volume
was defined as an MRI positive volume and the scans/
images/patient were denoted as MRI positive. An example of
GTVs in the right SV found in all three MRIs is shown in
Figure 1. For patients with no or non-confirmed GTV in the
T2w image, the MRI was defined as negative, see supplement
material S2.
Two CTVs were defined for the MRI positive volumes: the
MRI positive volume in the prostate (CTV_prostate_MRI)
and the MRI positive volume in the SV (CTV_SV_MRI).
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Three different PTV strategies were used when planning the
dose to the SV and prostate for each patient:
 PTV_MRIþ: the union of CTV_SV_MRI with 11mm margin
and CTV_prostate_MRI with a margin of 5mm/5mm/
7mm in the anterior–posterior (AP), left–right (LR) and
craniocaudal (CC) directions.
 PTV_SV 11mm: the union of CTV_SV with a margin of
11mm and CTV_prostate with a margin of 5mm/5mm/
7mm in the AP, LR and CC directions.
 PTV_SV 7mm: the union of CTV_SV with a margin of
7mm and CTV_prostate with a margin of 5mm/5mm/
7mm in the AP, LR and CC directions.
MRI positive volumes were transferred to the CT scan by a
deformable registration in SmartAdapt (Varian Medical sys-
tems, Palo Alto, CA).
Treatment planning
Treatment plans were calculated to deliver 78Gy in 39 frac-
tions to the entire PTV of the respective planning strategy.
All plans were volumetric arc plans and normalized to a
mean dose of 78Gy to the relevant PTV. The majority (61 out
of 63) of plans were optimized with RapidPlan using the clin-
ically commissioned algorithm PO 13.6.23 (Varian Medical
Systems, Palo Alto, CA). The remaining two plans were opti-
mized without using the RapidPlan model but using the
same optimization module. The model in RapidPlan had
been trained with a representative selection of 34 clinically
approved plans for prostate cancer patients with target being
the prostate and SV. The planning goal was to ensure that
95% of the respective PTV should be covered by 98% of the
prescribed dose as the highest priority. Dose to rectum, blad-
der and femoral heads were included in the optimization to
ensure the lowest dose possible without compromising the
dose coverage of the PTV. An example is shown in supple-
mentary material S3 of the dose distribution for a MR
þ11mm plan with the contours for the PTVs for the SV 11
and SV 7mm plans shown for comparison.
In addition to organ at risk doses, conformity index (CI)
and homogeneity index (HI) were calculated as follows:
CI¼ volume of the 98% isodose/volume of the PTV [10].
HI¼ (D2–D98%)/D50%, where DX% is the minimum dose to
X% of the volume of the PTV and were extracted from the
dose-volume-histograms (DVH) of the PTV dose coverage [11].
Statistical comparison of dose and planning metrics was
performed by Wilcoxon signed rank test using a two-sided
significance level of 0.05. Comparison of CI and HI between
the MRI positive and MRI negative groups were performed
by two-sample t-test with a significance level of 0.05.
NTCP and TCP modeling
The NTCP of rectal toxicity of grade 2 was modeled using
the Lyman–Kutcher–Burman formulation from the QUANTEC
paper using the parameters n¼ 0.09, m¼ 0.13 and
TD50¼ 76.9 Gy [12,13] and DVH for the rectum. The equation
is included in the supplementary material S4. The model par-
ameter n describes the volume effect, m the slope of the
dose-response curve and TD50 the uniform dose correspond-
ing to a 50% risk of complications. The bladder NTCP for
grade 1 was modeled using the equations in supplemen-
tary material S4 using the parameters n¼ 0.00995, m¼ 0.022
and TD50¼ 77.6 Gy [14].
TCP was modeled using a logistic dose-response function
with parameters defined through a meta-analysis of random-
ized dose escalation trials [15,16]. The equation was included
in the supplementary material S4. Calculations were per-
formed with c50¼0.78 as the slope of the dose-response
curve. The uniform dose corresponding to 50% probability of
tumor control D50 is calculated by requiring TCP (78Gy)¼ 0.
80 leading to D50¼54Gy [15,17]. The dose entered in the
TCP calculation was the mean dose to PTV_MRIþ (the MRI
positive PTV in both SV and prostate). Please note that this
definition of the target is an important modeling decision; it
reflects an ansatz that MRI correctly defines the tumor mass
Figure 1. Example of a suspicious volume in the right side of the SV found in the T2w image and confirmed by both ADC and Ktrans map. The blue, pink and green
contours are the delineated GTVs in the T2w image, the ADC map and the Ktrans map, respectively. The Ktrans map is not calculated in the complete image due to
software limitations.
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and we investigate the potential benefits of individualized
target definition under this ansatz.
Results
For 14 of the 21 patients with evaluable scans MRI positive
volumes were detected. For six of these patients, the MRI
positive volume in the T2w image was confirmed by both
functional scans.
The results showed that TCP for the MR þ11mm plan was
significantly higher compared to the SV 7 and SV 11mm plans
with p¼ .0001 and p¼ .03, respectively. The median rectal
NTCP for the MR þ11mm plans were 10% (4–15%).
Comparing rectal NTCP of grade 2 for the SV 7 and SV
11mm plans, including both MRI positive and MRI negative
patients, the NTCP of grade 2 increased from a median of
median 8% (2–21%) to a median of 15% (3–33%). Rectal tox-
icity NTCP for grade 2 was not statistical significantly different
(p¼ .67) between the MR þ11 and SV 7mm plans (Figure 2).
The rectal NTCP for grade 2 the SV 11mm plans were signifi-
cantly higher compared to the MR þ11mm plans and SV
7mm plans with p<.001 for both. The results for the bladder
NTCP for grade 1 are shown in supplementary material S5.
The MR þ11mm plans had a significantly lower V70Gy and
V75Gy for the rectum compared to the SV 11mm plans of 43
and 46%, respectively (Table 1). Comparing MR þ11 and SV
7mm plans there was no statistical difference in the V70Gy
and V75Gy for the rectum (p> .3). The MR þ11mm plans had
a significantly lower V50Gy to the bladder of 54 and 41%
when compared to the SV 11 and SV 7mm plans, respect-
ively, both with p¼ .0001.
No statistical significant difference in homogeneity or con-
formity was observed between the MRI positive and MRI
negative patients. Comparing the different types of plans for
the MRI positive patients there was no statistical significant
different in HI and CI for MR þ11mm and SV 7mm, CI was
statistically higher for MR þ11mm compared to SV 11mm
plans but HI was not statistically different. Comparison of SV
11 and SV 7mm showed a statistical higher CI and a statis-
tical lower HI for SV 7mm.
Discussion
In this study the impact of using MRI for delineation of tar-
gets in the SV was investigated. Three treatment strategies
were compared: one targeting the MRI positive volumes in
SV and prostate with a margin of 11mm to the MRI positive
volume in the SV and two targeting the SV and prostate
with margins to the SV of 11 and 7mm, respectively. We cal-
culated the TCP under the assumption that the MRI positive
volume was the crucial part of the SV to target. Under this
assumption, we showed that treating MRI positive volumes
with appropriate margins could significantly improve the TCP
by up to 11% (on average 3%) without a significant increase
in rectal NTCP of grade 2 compared to the SV 7mm plans.
The NTCP grade 1 for the bladder was calculated and
showed a large variability as the NTCP grade 1 is modeled
with the bladder as a serial organ highly dependent on hot-
spots. The results of the bladder NTCP grade 1 should be
interpreted with caution because the model contains large
uncertainties originating from a poor relation between dose-vol-
ume effects, large deformability and variability in volume [18].
The SV 7mm plans resembled a clinical plan and were for
this work used as a standard when comparing the treatment
plans. This approach was chosen as the complete SV typically
was not included clinically unless the patient had been clinic-
ally staged with SV involvement (stage T3b) where the com-
plete organ would have been included (as explained in the
materials and methods section). The clinical staging and the
finding of a MRI positive volume in the SV did not agree for
all patients (see supplementary material S1) which corres-
pond to studies which have investigated the diagnostic value
of DWI and DCE MRI information [9].
The evaluation of TCP on the PTV is an approximation
because it is truly the CTV that contains tumor cells.
However, the CTV do not include effects of motion during
the treatment course but by evaluation of the dose distribu-
tion to the PTV we used this as surrogate for the resulting
dose distribution to the MRI positive volume. A more
Figure 2. Estimates of the NTCP for rectal toxicity higher than grade 2 (A) and
estimated TCP (B). The horizontal axes are the estimates for the plan SV 7mm.
The vertical axes are the estimates of the plan SV 11mm and MRþ 11mm.
See text and supplementary material for details on calculations and plan defini-
tions. Circles and crosses indicate plans for MRI positive and MRI negative
patients, respectively. The line of identity is depicted with a slashed line in
gray. The rectal NTCP of grade 2 for the SV 7mm plans were not significantly
different from the MRþ11mm plans (p¼ .76). The TCP for the MRþ 11mm
plans were significantly higher compared to the SV 7 and SV 11mm plans
(p .03)
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accurate TCP could have been estimated if MRI information
had been available from every treatment fraction or alterna-
tive a simulation of the movement could have been per-
formed similar to [19]. If tumor involvement was present
outside of the MRI positive volume, there is a risk of
decreased TCP due to the compromise of radiation to other
parts of the SV.
Where the NTCP modeling follows conventional argu-
ments, TCP modeling of prostate cancer when compromising
part of the target cannot at present be done without simpli-
fying assumptions as applied here. The TCP model used
dose-response data from randomized trials and uses mean
dose to target as carrier of TCP. Furthermore, the TCP model
assumes that the MRI positive regions of the target were
indeed the driver of recurrence risk. Consequently, the main
risk would be false negative regions of the SV, which should
have been targeted and were not penalized by the models.
Thus the TCP modeling uncertainty was associated with the
uncertainties of MRI defining the cancer as discussed below.
In 6 out of 14 patients, positive volumes were observed in
all types of MR images. The functional DWI and DCE MRI has
shown great potential for distinguishing malignant from non-
malignant tissue [5,9,20]. Sensitivity and specificity within the
prostate has been reported to be above 90% using a 1.5T scan-
ner [21]. In supplementary material S1, the characteristic of the
patient group is shown stratified for patients with MRI positive/
negative images. For patients with MRI positive images, 5 out
of 14 (36%) had two clinical high-risk features and 9 out of 14
(64%) had three high-risk features. Compared to the patients
with MRI negative images, 5 out of 7 (71%) and 2 out of 7
(29%) had two and three high-risk features, respectively.
In this study we presupposed that a potential MRI positive
volume should be visible in the T2w MRI. The reason for this
choice was that the anatomical information in the functional
images were limited, for especially the Ktrans maps, and sub-
jected to artifacts, especially the ADC maps, from the
implanted seeds and gas in the rectum. The choice was
more practical than clinical and improving the registration of
the DWI and DCE to the T2w MRI, as has been done for brain
targets, would make it more reliable to connect volumes in
the functional scans to the anatomical scans and would give
rise to extended use of the functional MRI.
In the pelvic area there can be both slow movements and
fast transient movements which can be challenging if scans
are recorded during such a movement since it is possible
that it causes deformations and hence change the anatomy
from one MRI sequence to the next. In the calculation of the
Ktrans map an auto-registration of the single MR images was
performed to correct for movements between images but for
some patients with large movements the correction was not
sufficient causing an increased uncertainty in the Ktrans map.
The ADC maps of some patients had many artifacts in the
area of the SV, probably due to gas in the rectum. The regis-
tration of the Ktrans and ADC maps to the T2w image was
performed manually. We transferred the GTV delineation
from the T2w image to the CT for treatment planning by
deformable registration. The deformable registration was not
able to correct for all changes in anatomy so for several
patients the GTV found in the SV of the MRI extended out of
the SV delineated in the CT which indeed introduced a sys-
tematic error. If volumes outside the prostate should be
transferred to the CT, further work should be done on the
registration of the different images to increase the precision.
The HI and CI for the SV 7mm plans compared to the SV
11mm plans were statistically significantly lower and higher,
respectively. However, for the HI and CI for the MR þ11mm
plans no statistical difference was seen when comparing to SV
7mm. This could be a result of RapidPlan was trained with
plans similar to the SV 7mm plans whereas the SV 11mm
plans have a larger PTV giving less distance to OAR and stress-
ing the constraints for tumor coverage and OAR compromise. It
is the opposite case for the MR þ11mm plans which had a
smaller PTV making it easier for the algorithm to meet the con-
straints. However, it is possible the dose to the OAR could be
reduced further for the MR þ11mm plans since the RapidPlan
used the same constraints regardless of the PTV size.
A number of weaknesses and limitations regarding the MR
images of this study should be acknowledged. In the study
we employed a surface coil. Using an endorectal coil
improves the signal-to-noise ratio resulting in higher quality
images and possibly better ability to distinguish malignant
and nonmalignant tissue [22]. However, an endorectal coil
could deform the prostate and SV introducing a systematic
error because it is not present at the treatment. Furthermore,
it could be hypothesized that using higher field strength for
functional MRI could lead to greater sensitivity [23]. However,
higher field strength increases the geometric distortion and
accuracy in the radiotherapy treatment [23]. In addition to
Table 1. Descriptive dose-volume and plan quality metrics for the three plan types. Values are median (range). The ideal CI and HI values were 1 and 0, respect-
ively. Comparing the high dose volumes for MR þ11 and SV 7mm plans no statistical significance was found for rectum (p>.3) but for the bladder the V50Gy
was significantly lower for the MR þ11mm plan (p¼.0001). The first three columns are data from MRI positive patients and the last three columns are from MRI
negative patients.
MRþ 11mm
MR positive
SV 11mm
MR positive
SV 7mm
MR positive
MRþ 11mm
MR negative
SV 11mm
MR negative
SV 7mm
MR negative
Conformity index 0.92
(0.83–0.98)
0.90
(0.82–0.94)
0.94
(0.90–0.98)
– 0.91
(0.88–0.93)
0.95
(0.90–0.95)
Homogeneity index 0.077
(0.068–0.091)
0.080
(0.070–0.109)
0.073
(0.065–0.086)
– 0.085
(0.081–0.093)
0.079
(0.076–0.090)
V75Gy for rectum [cm
3] 6.0
(2.3–10.7)
11.2
(1.5–22.3)
6.2
(1.3–13.0)
– 9.2
(5.0–16.1)
4.7
(1.5–8.1)
V70Gy for rectum [cm
3] 8.8
(3.7–13.7)
15.5
(3.5–32.8)
9.7
(2.9–19.5)
– 14.9
(9.4–22.2)
8.0
(3.6–13.6)
V50Gy for bladder [cm
3] 29.7
(20.3–39.9)
65.2
(38.8–107.9)
50.6
(30.7–82.7)
– 60.7
(38.4–79.2)
48.4
(31.4–64.9)
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this there is an inter-observer uncertainty in the delineations
of the GTVs in the T2w, DWI and DCE MRI as they were per-
formed by one radiation oncologist.
Kerstin et al. suggested that including the most proximal
2 cm of the SV in the CTV would be sufficient to cover the
spread of cancerous cells in 99% of all patients. However,
they mention that the appropriate dose to be delivered to
the SV is not known. For this reason, many institutions have
implemented relatively small PTV margins (5–7mm) with an
image-guidance strategy based on prostate markers as
opposed to the 11mm suggested by de Boer et al. as neces-
sary to cover the full extent of the CTV_SV. It should be
noted that the most distal part of the SV is more movable
and hence requires larger margin [1]. As a cautionary note to
this strategy, studies have indicated potential loss of bio-
chemical control in patients with large rectal extend at plan-
ning, which could be due to motion aspects [24,25]. While
the fiducial marker image guidance will cover the prostate
motion of such patients, the above-mentioned margins may
be insufficient to include SV which may be particularly prob-
lematic if the MRI scans indicate SV involvement.
In this study we showed that when treating prostate cancer
patients with risk of SV involvement but target the MRI suspi-
cious volume in the SV with an appropriate margin of 11mm,
the rectal NTCP for grade 2 is decreased 34% compared to
target the entire SV volume. The TCP increased with up to 11%
(on average by 3%) when estimated using the assumption that
control depended on the dose coverage of the MRI positive
volume with a PTV margin of 11mm. Though the use of MR
images to identify SV involvement needs to be clinically vali-
dated, it would provide the possibility to identify patients with
SV involvement (intermediate or high-risk patients) directly,
instead of relying on a probability based on general clinical fea-
tures. This would, in turn, enable treating only the involved SV
volume using larger margins only in a subset of patients.
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